{"id":"W3080672747","doi":"10.1016/j.clml.2020.08.008","title":"Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Research and Development; Takeda Canada; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Janssen Biotech; Roche; GlaxoSmithKline; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Multiple myeloma; Lenalidomide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002356836,0.0007121026,0.001358191,0.0004649544,0.0003975199,0.0006245188,0.0005733622,0.0005921148,0.001255678],"category_scores_gemma":[0.0009976916,0.0003330209,0.0009091552,0.000443984,0.0004044871,0.0007042522,0.0003774927,0.001856412,0.0003799669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008120791,"about_ca_system_score_gemma":0.0007745388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006113822,"about_ca_topic_score_gemma":0.001634137,"domain_scores_codex":[0.9993981,0.0002686012,0.00005975924,0.00009250256,0.00009115673,0.00008982654],"domain_scores_gemma":[0.9994562,0.0001025491,0.0001479782,0.00004831358,0.00004319305,0.0002016801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.3406019,0.04440033,0.04126133,0.001593894,0.002136395,0.001230421,0.00072508,0.005029089,0.05949175,0.0003761264,0.004783247,0.4983704],"study_design_scores_gemma":[0.3055656,0.5816253,0.07568576,0.0002080627,0.001564238,0.002217695,0.0001165867,0.006163074,0.01399789,0.0004213297,0.01237762,0.00005689619],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991924,0.00588763,0.0002513897,0.0003595242,0.00006965909,0.0003891122,0.0001474125,0.00005665319,0.0009145938],"genre_scores_gemma":[0.9960432,0.001513933,0.0008222769,0.000464479,0.0001266948,0.0002272979,0.0002734706,0.000009368391,0.0005194083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002356836,"threshold_uncertainty_score":0.01246434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0549864414527626,"score_gpt":0.3589540105480418,"score_spread":0.3039675690952792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}